Pub Date : 2018-06-01DOI: 10.3138/JAMMI.2018.02.14
L. Valiquette, K. Laupland
{"title":"Fasten your seatbelts: 2018–2019 influenza season is coming","authors":"L. Valiquette, K. Laupland","doi":"10.3138/JAMMI.2018.02.14","DOIUrl":"https://doi.org/10.3138/JAMMI.2018.02.14","url":null,"abstract":"","PeriodicalId":36782,"journal":{"name":"JAMMI","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2018-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.3138/JAMMI.2018.02.14","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"44086335","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2018-06-01DOI: 10.3138/JAMMI.2018.01.04
Adam R. Houston, Catherine-Marie Blais, S. Houston, B. J. Ward
Many essential medicines, including basic drugs such as albendazole, do not have approval to be marketed in Canada. Instead, they are only available through a federal government mechanism: the Special Access Programme (SAP). SAP was designed as a mechanism to provide emergency access to new drugs not yet authorized for sale, not for proven medicines that appear on the World Health Organization (WHO) Model List of Essential Medicines. Because it was never intended or designed to fulfill this function, SAP creates needless access barriers that inhibit timely and effective care, particularly for patients with tropical, parasitic, and other infectious diseases. Regulatory changes to resolve this problem are readily achievable and should be prioritized.
{"title":"Reforming Canada’s Special Access Programme (SAP) to improve access to off-patent essential medicines","authors":"Adam R. Houston, Catherine-Marie Blais, S. Houston, B. J. Ward","doi":"10.3138/JAMMI.2018.01.04","DOIUrl":"https://doi.org/10.3138/JAMMI.2018.01.04","url":null,"abstract":"Many essential medicines, including basic drugs such as albendazole, do not have approval to be marketed in Canada. Instead, they are only available through a federal government mechanism: the Special Access Programme (SAP). SAP was designed as a mechanism to provide emergency access to new drugs not yet authorized for sale, not for proven medicines that appear on the World Health Organization (WHO) Model List of Essential Medicines. Because it was never intended or designed to fulfill this function, SAP creates needless access barriers that inhibit timely and effective care, particularly for patients with tropical, parasitic, and other infectious diseases. Regulatory changes to resolve this problem are readily achievable and should be prioritized.","PeriodicalId":36782,"journal":{"name":"JAMMI","volume":"1 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2018-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.3138/JAMMI.2018.01.04","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"41551161","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Streptococcus pneumoniae is an encapsulated bacterium capable of causing invasive disease in susceptible individuals, including immunocompromised and asplenic patients. Wiskott-Aldrich syndrome (WAS) is a primary immunodeficiency disease with myriad manifestations; it can cause thrombocytopenia, platelet dysfunction, selective antibody deficiency, and predisposition to bacterial infections. A 24-year-old Métis man presented to a Northern Ontario emergency department with several days’ history of malaise, headache, and nuchal rigidity. Within 5 months, he presented again with similar symptoms. In both instances, S. pneumoniae serotype 15C was isolated from his cerebrospinal fluid. He was successfully treated with cefotaxime both times. The patient’s past medical history included WAS, splenectomy, Epstein-Barr virus-associated lymphoma treated with bone marrow transplant, and prior cases of pneumococcal meningitis and pneumonia. He was restarted on indefinite penicillin V prophylaxis. This is the first described case of WAS in a man of mixed European and Indigenous North American descent. We report recurrent invasive pneumococcal disease in an asplenic individual caused by an emerging invasive serotype.
{"title":"Recurrent meningitis caused by Streptococcus pneumoniae serotype 15C associated with Wiskott-Aldrich syndrome","authors":"Vic Eton, James Beveridge, M. Ulanova","doi":"10.3138/JAMMI.2017-0007","DOIUrl":"https://doi.org/10.3138/JAMMI.2017-0007","url":null,"abstract":"Streptococcus pneumoniae is an encapsulated bacterium capable of causing invasive disease in susceptible individuals, including immunocompromised and asplenic patients. Wiskott-Aldrich syndrome (WAS) is a primary immunodeficiency disease with myriad manifestations; it can cause thrombocytopenia, platelet dysfunction, selective antibody deficiency, and predisposition to bacterial infections. A 24-year-old Métis man presented to a Northern Ontario emergency department with several days’ history of malaise, headache, and nuchal rigidity. Within 5 months, he presented again with similar symptoms. In both instances, S. pneumoniae serotype 15C was isolated from his cerebrospinal fluid. He was successfully treated with cefotaxime both times. The patient’s past medical history included WAS, splenectomy, Epstein-Barr virus-associated lymphoma treated with bone marrow transplant, and prior cases of pneumococcal meningitis and pneumonia. He was restarted on indefinite penicillin V prophylaxis. This is the first described case of WAS in a man of mixed European and Indigenous North American descent. We report recurrent invasive pneumococcal disease in an asplenic individual caused by an emerging invasive serotype.","PeriodicalId":36782,"journal":{"name":"JAMMI","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2018-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.3138/JAMMI.2017-0007","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"49461479","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
京公网安备 11010802042870号
京ICP备2023020795号-1
扫码关注我们
求助内容：
应助结果提醒方式：